When Ayoka was admitted to a hospital in Zambia with severe pneumonia, her family faced weeks of worry—and mounting bills. Like millions of families across Africa, they watched their daughter receive injectable antibiotics day after day, even as she began to get better. A new study suggests that doesn't have to be the norm.
Researchers led by City St George's, University of London and University College London found that children hospitalized with severe pneumonia can safely switch from injectable antibiotics to oral pills once they start recovering. The clinical trial, called PediCAP, followed 1,101 children between 2 months and 6 years old at 13 hospitals across South Africa, Uganda, Zambia, Zimbabwe, and Mozambique.
The results, published in the medical journal The Lancet, showed that children who switched to oral antibiotics got just as well as those who stayed on injectable treatment for the full five days recommended by the World Health Organization (WHO). Hospital readmission or death rates within 28 days were nearly identical: 6% for children taking oral amoxicillin, 7% for those on oral amoxicillin-clavulanate, and 6% for children receiving the standard injectable antibiotics.
Beyond safety, the switch offered practical benefits. Children who moved to oral antibiotics left the hospital about one day earlier. Researchers also found that a total antibiotic course of four to five days worked just as well as longer courses of seven or eight days, meaning many children could receive substantially less antibiotic treatment overall.
Amoxicillin—the simpler, cheaper antibiotic—performed just as well as the broader-spectrum amoxicillin-clavulanate, which is good news for hospitals working with limited budgets.
"Every year millions of children around the world are admitted to the hospital with severe pneumonia," said Professor Julia Bielicki of City St George's, University of London, who co-led the study. "Our study shows that once a child is clinically improving, it is safe to switch from injectable to oral antibiotics and complete treatment at home."
Pneumonia remains one of the leading infectious killers of children worldwide, especially in low- and middle-income countries. Longer hospital stays burden families with costs, keep beds occupied in already stretched facilities, and increase the risk of catching antibiotic-resistant infections while in the hospital.
Dr. Michelle Clements, principal statistician at UCL who also co-led the trial, noted that PediCAP was the first large-scale study to test multiple antibiotics and treatment lengths at once. "This approach allowed us to establish that the shortest studied treatment strategy was effective and safe," she said.
Because amoxicillin is affordable and available in nearly every country, the researchers believe their findings could change how hospitals worldwide treat childhood pneumonia—helping children get back to their families sooner while easing pressure on health systems.